We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
May be
But I personally we will see some very big delayed orders after 4 o’clock
At mates rates
Hold !
Wiggly - no I’m talking revenue - Avacta’s contribution is one small but essential part of the lateral flow test . There are a lot of other costs involved; packaging, distribution, the manufacture of the kit itself- so i don’t reckon that Avacta’s share will be more than a quid a pop . Is there any basis to to saying Avactas revenue will be a third of the total revenue for the UK govt contracts or is that also just a guess . Great if it is > £1.50 a shot but even at 50p a shot that is still a decent foundation to build on and justifies a higher market cap , say 3X current I.e 20 X £80m turnover , on the expectation of accelerating growth and other offerings .
is Miton still reducing?
Well remembered.
Sensitivity 100% @ Ct<27 is “EXQUISITE”
The future's bright, the future's Avacta!
Great post - more like this please......pro investing, less dreaming!
If the Mrs finds out that Avacta have dropped 8p she’s gonna leave me
8p!!!
Oh dear, oh dear oh dear, ..........oh dear oh dear oh dear!
Avacta delivered the cv results we all wanted but the market failed to deliver the massive rise a few were automatically expecting. Then just to rub it in the market pours cold water on today’s excellent results presentation.
Avacta, never fails to disappoint some, but seems to have pleased the majority here today. All I can say, yet again, is thank you AS and team. The strategy now being played out here will favour those invested for the long game. I’m sure today will have seriously ****** off the get rich quick brigade. They’ll have finally realised that the end of this rainbow is more than a few weeks/months away and the prospect of getting a massive spike looking less likely. It will be a long steady climb but with a good few dips along the way no doubt. As many posters have already pointed out, the pipeline of Avacta news is massive and will potentially richly reward investors who hold over the next few years!
Avacta were never about carrying out a smash and grab raid on the Covid test market. I’ve got sod all business acumen but even I can see that the underlying strategy has always been about underpinning the future of Avacta, growing (and protecting) its IP and reputation and building a diagnostic brand that will be recognised and trusted around the world for years to come (unless they sell it off!). Regardless of what our lfd manufacturing capacities turn out to be the path taken here has also ensured we have a reputation for delivering quality products. It has given us access to partners for product development, manufacturing and commercialisation and potentially a solid network of distributors, end-users and OEM partners. Besides the cash that will come soon, it’s these aspects which will also help build a great future for the diagnostics business as a whole over the next few years.
Sensitivity 100% @ Ct<27 is “EXQUISITE”
The future's bright, the future's Avacta!
ATB
Concur entirely, DonaldTrumpsWig's musing has to be post of the day, thus far.
Trumpwig- excellent post.
I actually think the recovery is very telling of the sentiment here. What usually happens with AIM stocks is significant rise into presentation and then huge dump. This has stayed pretty robust in comparison. ORR dropped by c30% before/after presentation recently. Have seen it time and time again.
Looking at the sells.some times better to see sellers out before more news is released. As seen with so much selling at GDR ,now the number of buyers again.will the sellers here think they have made a! mistake if more blue days seen soon.
Please excuse the copy/paste DonaldTrumpsWig, but your post is epic:
Company with fantastic IP in cancer therapies pivots to meet unexpected and unprecedented demand for CV test.
From standing start, during a pandemic, delivers world class LFT whilst navigating inevitable delays, wrong choice of partners, regulatory hurdles, changes in sample collection methods etc etc
Whilst all this is going on, maintaining cancer pipeline and signing license agreements with numerous partners all of whom irrevocably endorse the IP of affimers
Today the CEO confirms all of the above, stating that demand is almost unlimited and the remaining hurdle is simply production capacity.
Two choices for shareholders:
Choice one, recognise that this is a unicorn investment opportunity, turn off you phone, enjoy the sunshine safe in the knowledge that the SP will take care of itself.
Choice two, refresh this BB and the SP every two minutes thus letting Nd and the other bedwetters get inside your head by overanalysing every nuance.
This is the investment opportunity of a generation, nothing said today has diminished that. The final hurdle for me was CV and that was cleared with ease. Find a beer garden and enjoy.
Yep you nailed it there DonaldTrumpsWig, great post
A wig and a beard in this thread. Fascinating the names people choose!
Please excuse the copy/paste DonaldTrumpsWig, but your post is epic:
Company with fantastic IP in cancer therapies pivots to meet unexpected and unprecedented demand for CV test.
From standing start, during a pandemic, delivers world class LFT whilst navigating inevitable delays, wrong choice of partners, regulatory hurdles, changes in sample collection methods etc etc
Whilst all this is going on, maintaining cancer pipeline and signing license agreements with numerous partners all of whom irrevocably endorse the IP of affimers
Today the CEO confirms all of the above, stating that demand is almost unlimited and the remaining hurdle is simply production capacity.
Two choices for shareholders:
Choice one, recognise that this is a unicorn investment opportunity, turn off you phone, enjoy the sunshine safe in the knowledge that the SP will take care of itself.
Choice two, refresh this BB and the SP every two minutes thus letting Nd and the other bedwetters get inside your head by overanalysing every nuance.
This is the investment opportunity of a generation, nothing said today has diminished that. The final hurdle for me was CV and that was cleared with ease. Find a beer garden and enjoy.
DonaldTrumpsWig. Superb mate.
Ticino, you are confusing Revenue with profit. £5 per test = revenue. Profit per test = 35%.
£5 was selected as its unlikely to be lower. Perhaps substantially higher to non GOv entities.
DonaldTrumpsWig - hear, hear...wise words!
Where do you get the £5 per unit . Avacta will sell the chemistry, and maybe only the IP , so I would have thought less than £1 per unit , which is £5m per month , so thats £40m for the rest year @ £1 per unit . Lets say they do 4X as much due to international interest at 50p per dose , then thats £80m .
Still thats massive as a first step and likely to be larger quantities.
Company with fantastic IP in cancer therapies pivots to meet unexpected and unprecedented demand for CV test.
From standing start, during a pandemic, delivers world class LFT whilst navigating inevitable delays, wrong choice of partners, regulatory hurdles, changes in sample collection methods etc etc
Whilst all this is going on, maintaining cancer pipeline and signing license agreements with numerous partners all of whom irrevocably endorse the IP of affimers
Today the CEO confirms all of the above, stating that demand is almost unlimited and the remaining hurdle is simply production capacity.
Two choices for shareholders:
Choice one, recognise that this is a unicorn investment opportunity, turn off you phone, enjoy the sunshine safe in the knowledge that the SP will take care of itself.
Choice two, refresh this BB and the SP every two minutes thus letting Nd and the other bedwetters get inside your head by overanalysing every nuance.
This is the investment opportunity of a generation, nothing said today has diminished that. The final hurdle for me was CV and that was cleared with ease. Find a beer garden and enjoy.
As Apre points out, the IIs probably liked what they were hearing and put in some wholesale orders. Hence, we take the hit.
In this hot Dx market, Dx companies are being purchased at 10x revenues, so even at this very low level (5m, which seems to be guaranteed at this stage, which equates to £300m annual revenues) would put a price tag of min £3b. But that does not consider the IP that has just been proved - so at least double the valuation to £6b. Then the Therapeutics. T/O price at these min levels would be huge.
Blue by close of play today and will rise to £2.80/90 by end of month. Just my opinion.
DYOR.
Lets just assume volumes max at only 5m per month..at only £5 per test, that's still over £300m in annual revenue. I think we can be 99.9% sure that our volumes will be multiples of 5m per month.
Yes hold on tight, the only way is up from here!!
I'm amazed we are not trading plus 300.
Major revenues look nailed on and imminent
Don’t look till tomorrow afternoon x